Ian James

Overview

Best Publications

• Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

  S. Mallal;S. Mallal;D. Nolan;C. Witt;C. Witt;G. Masel;G. Masel

  1725
  Citations

• Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA.

  Photini Kiepiela;Alasdair J. Leslie;Isobella Honeyborne;Danni Ramduth

  1002
  Citations

• Evidence of HIV-1 Adaptation to HLA-Restricted Immune Responses at a Population Level

  Corey B. Moore;Mina John;Ian R. James;Frank T. Christiansen;Frank T. Christiansen

  943
  Citations

• Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection.

  Simon A Mallal;Mina John;Corey B. Moore;Ian R. James

  633
  Citations

• Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant

  Annalise M. Martin;David Nolan;Silvana Gaudieri;Silvana Gaudieri;Coral Ann Almeida

  557
  Citations

• Immune restoration disease after the treatment of immunodeficient HIV‐infected patients with highly active antiretroviral therapy

  M.A. French;N. Lenzo;M. John;S.A. Mallal

  552
  Citations

• Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts

  Annalise M Martin;David Nolan;Ian James;Paul Cameron

  383
  Citations

• Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy

  Mina John;Corey B. Moore;Ian R. James;David Nolan

  332
  Citations

• Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580

  James G. Conway;Brad McDonald;Janet Parham;Barry Keith

  275
  Citations

• Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir

  David Nolan;Richard Upton;Elizabeth McKinnon;Mina John

  201
  Citations

• Population Level Analysis of Human Immunodeficiency Virus Type 1 Hypermutation and Its Relationship with APOBEC3G and vif Genetic Variation

  Craig Pace;Jean Keller;David Nolan;Ian James

  194
  Citations

• Improving the Effectiveness of Penicillin Allergy De-labeling.

  Jack Bourke;Jack Bourke;Rebecca Pavlos;Ian James;Elizabeth Phillips

  178
  Citations

• Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level.

  David Nolan;Emma Hammond;Ian James;Elizabeth McKinnon

  175
  Citations

• HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms.

  Katherine C. Konvinse;Jason A. Trubiano;Jason A. Trubiano;Rebecca Pavlos;Ian James

  167
  Citations

• Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype

  Alexandre Harari;Cristina Cellerai;Felicitas Bellutti Enders;Josef Köstler

  166
  Citations

• Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy.

  Silvana Gaudieri;Andri Rauch;Andri Rauch;Katja Pfafferott;Eleanor Barnes

  165
  Citations

• Population-based V3 Genotypic Tropism Assay: A Retrospective Analysis Using Screening Samples From the A4001029 and MOTIVATE Studies

  Rachel A McGovern;Alexander Thielen;Theresa Mo;Winnie Dong

  165
  Citations

• Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing.

  John Archer;Michael S Braverman;Bruce E Taillon;Brian Desany

  153
  Citations

• Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.

  Mina John;Elizabeth J. Mckinnon;Ian R. James;David A. Nolan

  145
  Citations

• Evidence of Viral Adaptation to HLA Class I-Restricted Immune Pressure in Chronic Hepatitis C Virus Infection

  Silvana Gaudieri;Andri Rauch;Lawrence P. Park;Elizabeth Freitas

  145
  Citations

• Proportions of circulating T cells with a regulatory cell phenotype increase with HIV-associated immune activation and remain high on antiretroviral therapy.

  Andrew Lim;Dino Tan;Patricia Price;Adeeba Kamarulzaman

  144
  Citations

• Immunological profiles of immune restoration disease presenting as mycobacterial lymphadenitis and cryptococcal meningitis

  D.B.A. Tan;Y.K. Yong;H.Y. Tan;A. Kamarulzaman

  142
  Citations

• Divergent Adaptation of Hepatitis C Virus Genotypes 1 and 3 to Human Leukocyte Antigen-Restricted Immune Pressure

  Andri Rauch;Ian James;Katja Pfafferott;David Nolan

  102
  Citations